5 results on '"Celli, Bartolome R."'
Search Results
2. Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians
- Author
-
Criner, Gerard J., Agustí García-Navarro, Àlvar, Borghaei, Hossein, Friedberg, Joseph, Martinez, Fernando J., Miyamoto, Curtis, Vogelmeier, Claus F., and Celli, Bartolome R.
- Subjects
Pulmonary and Respiratory Medicine ,Càncer de pulmó ,Review ,Chronic obstructive pulmonary diseases ,Lung cancer ,Malalties pulmonars obstructives cròniques - Abstract
Chronic obstructive pulmonary disease (COPD) and lung cancer are common global causes of morbidity and mortality. Because both diseases share several predisposing risks, the 2 diseases may occur concurrently in susceptible individuals. The diagnosis of COPD has important implications for the diagnostic approach and treatment options if lesions concerning for lung cancer are identified during screening. Importantly, the presence of COPD has significant implications on prognosis and management of patients with lung cancer. In this monograph, we review the mechanistic linkage between lung cancer and COPD, the impact of lung cancer screening on patients at risk, and the implications of the presence of COPD on the approach to the diagnosis and treatment of lung cancer. This manuscript succinctly reviews the epidemiology and common pathogenetic factors for the concurrence of COPD and lung cancer. Importantly for the clinician, it summarizes the indications, benefits, and complications of lung cancer screening in patients with COPD, and the assessment of risk factors for patients with COPD undergoing consideration of various treatment options for lung cancer.
- Published
- 2022
3. Additional file 1 of Comorbidities and mortality risk in adults younger than 50 years of age with chronic obstructive pulmonary disease
- Author
-
Divo, Miguel J., Marin, José M., Casanova, Ciro, Cabrera Lopez, Carlos, Pinto-Plata, Victor M., Marin-Oto, Marta, Polverino, Francesca, de-Torres, Juan P., Billheimer, Dean, and Celli, Bartolome R.
- Abstract
Additional file 1: Figure S1. Comorbidities prevalence bar graph comparing Young (≤ 50 years) and older (> 50 years) COPD patients. Figure S2. Kaplan–Meier survival curve comparing the three groups. In blue is the control group, red for “Young COPD” and green for the older COPD. Figure S3. Primary causes of death in the Young (< 50 years) and “Older” COPD patients (> 50 years). Table S1. Comorbidities prevalence comparison between Young COPD and controls. Table S2. Comorbidities prevalence comparing Young COPD and Old COPD.
- Published
- 2022
- Full Text
- View/download PDF
4. Optimal NIV Medicare Access Promotion: Patients With COPD: A Technical Expert Panel Report From the American College of Chest Physicians, the American Association for Respiratory Care, the American Academy of Sleep Medicine, and the American Thoracic Society
- Author
-
Hill, Nicholas S, Criner, Gerard J, Branson, Richard D, Celli, Bartolome R, MacIntyre, Neil R, Sergew, Amen, and ONMAP Technical Expert Panel
- Subjects
Chronic Obstructive ,Chronic Obstructive Pulmonary Disease ,Clinical Trials and Supportive Activities ,Clinical Sciences ,Respiratory System ,ONMAP Technical Expert Panel ,Bioengineering ,mechanical ventilation ,Medicare ,hypercapnic respiratory failure ,Pulmonary Disease ,Clinical Research ,Humans ,COPD ,Airway Management ,Lung ,Assistive Technology ,Noninvasive Ventilation ,Continuous Positive Airway Pressure ,Patient Selection ,noninvasive ventilation ,Home Care Services ,United States ,Good Health and Well Being ,Practice Guidelines as Topic ,Respiratory ,Patient Participation ,Respiratory Insufficiency - Abstract
This document summarizes the work of the COPD Technical Expert Panel working group. For patients with COPD, the most pressing current coverage barriers identified were onerous diagnostic requirements focused on oxygenation (rather than ventilation) and difficulty obtaining bilevel devices with backup rate capabilities. Because of these difficulties, many patients with COPD were instead sometimes prescribed home mechanical ventilators. Critical evidence supports changes to current policies, including randomized controlled trial evidence suggesting a mortality benefit from bilevel positive airway pressure with backup rate and updated clinical practice guidelines from the American Thoracic Society as well as the European Respiratory Society. To achieve optimal access to noninvasive ventilation for patients with COPD, we make the following key recommendations: (1) removal of the need for overnight oximetry testing; (2) the ability to initiate therapy using bilevel devices with backup rate capability; and (3) increased duration of time to meet adherence criteria (ie, a second 90-day trial period) in those patients actively engaged in their care. Clear guidelines based on medical necessity are also included for patients who require initiation of or switch to a home mechanical ventilator. Adoption of these proposed recommendations would result in the right device, for the right type of patient with COPD, at the right time. Finally, we emphasize the need for adequate clinical support during initiation and maintenance of home noninvasive ventilation in such patients.
- Published
- 2021
5. Association Between Interstitial Lung Abnormalities and All-Cause Mortality
- Author
-
Putman, Rachel K, Hatabu, Hiroto, Araki, Tetsuro, Gudmundsson, Gunnar, Gao, Wei, Nishino, Mizuki, Okajima, Yuka, Dupuis, Josée, Latourelle, Jeanne C, Cho, Michael H, El-Chemaly, Souheil, Coxson, Harvey O, Celli, Bartolome R, Fernandez, Isis E, Zazueta, Oscar E, Ross, James C, Harmouche, Rola, Estépar, Raúl San José, Diaz, Alejandro A, Sigurdsson, Sigurdur, Gudmundsson, Elías F, Eiríksdottír, Gudny, Aspelund, Thor, Budoff, Matthew J, Kinney, Gregory L, Hokanson, John E, Williams, Michelle C, Murchison, John T, MacNee, William, Hoffmann, Udo, O'Donnell, Christopher J, Launer, Lenore J, Harrris, Tamara B, Gudnason, Vilmundur, Silverman, Edwin K, O'Connor, George T, Washko, George R, Rosas, Ivan O, Hunninghake, Gary M, Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators, and COPDGene Investigators
- Subjects
Male ,Chronic Obstructive ,Chronic Obstructive Pulmonary Disease ,Coronary Artery Disease ,Medical and Health Sciences ,Pulmonary Disease ,Cohort Studies ,Clinical Research ,Neoplasms ,Cause of Death ,General & Internal Medicine ,Genetics ,Prevalence ,Humans ,Prospective Studies ,Aetiology ,Lung ,Proportional Hazards Models ,COPDGene Investigators ,Human Genome ,Smoking ,Radiography ,Pulmonary Emphysema ,Respiratory ,Female ,Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators ,2.4 Surveillance and distribution - Abstract
ImportanceInterstitial lung abnormalities have been associated with lower 6-minute walk distance, diffusion capacity for carbon monoxide, and total lung capacity. However, to our knowledge, an association with mortality has not been previously investigated.ObjectiveTo investigate whether interstitial lung abnormalities are associated with increased mortality.Design, setting, and populationProspective cohort studies of 2633 participants from the FHS (Framingham Heart Study; computed tomographic [CT] scans obtained September 2008-March 2011), 5320 from the AGES-Reykjavik Study (Age Gene/Environment Susceptibility; recruited January 2002-February 2006), 2068 from the COPDGene Study (Chronic Obstructive Pulmonary Disease; recruited November 2007-April 2010), and 1670 from ECLIPSE (Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints; between December 2005-December 2006).ExposuresInterstitial lung abnormality status as determined by chest CT evaluation.Main outcomes and measuresAll-cause mortality over an approximate 3- to 9-year median follow-up time. Cause-of-death information was also examined in the AGES-Reykjavik cohort.ResultsInterstitial lung abnormalities were present in 177 (7%) of the 2633 participants from FHS, 378 (7%) of 5320 from AGES-Reykjavik, 156 (8%) of 2068 from COPDGene, and in 157 (9%) of 1670 from ECLIPSE. Over median follow-up times of approximately 3 to 9 years, there were more deaths (and a greater absolute rate of mortality) among participants with interstitial lung abnormalities when compared with those who did not have interstitial lung abnormalities in the following cohorts: 7% vs 1% in FHS (6% difference [95% CI, 2% to 10%]), 56% vs 33% in AGES-Reykjavik (23% difference [95% CI, 18% to 28%]), and 11% vs 5% in ECLIPSE (6% difference [95% CI, 1% to 11%]). After adjustment for covariates, interstitial lung abnormalities were associated with a higher risk of death in the FHS (hazard ratio [HR], 2.7 [95% CI, 1.1 to 6.5]; P = .03), AGES-Reykjavik (HR, 1.3 [95% CI, 1.2 to 1.4]; P
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.